A new strategy for delivering bulky PROTACs to cancerous cells successfully utilizes the CD36 protein pathway on cells’ surfaces.

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York ...

binding to both a target protein and a ligase to drive ubiquitination and catalytic degradation of the target through the proteasome. The new deg suffix is an important recognition that the ...

"Cells have two important 'junk compartments': the lysosome and the proteasome," Silverman said. "They collect junk and other components that are not useful to the cell, chew them up and get rid ...

Taken together, these findings demonstrate that interferon triggers PARP14-mediated ADP-ribosylation in p62 bodies, which requires an active ubiquitin-proteasome system. Interferon induces the ...

Bavdegalutamide (ARV-110) is a PROteolysis TArgeting Chimera (PROTAC) protein degrader that recruits the cereblon-containing E3 ubiquitin ligase to direct the polyubiquitination and subsequent ...

aThe Cardiac Exercise Research Group at the Faculty of Medicine and Health Sciences, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway ...

The review by Yongmei Wang et al., “The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy,” provides a comprehensive analysis of the UPS’s role in ...

It moves around looking for damaged mitochondria, and when it finds them, it creates a protein called ubiquitin that signals the body to get rid of them. When that PINK1 protein mutates ...